Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (EBS) has completed the repurchase of $75 million aggregate principal of its 3.875% Senior Unsecured Notes due 2028, as authorized by its board.
The company spent approximately $68 million of cash, implying an average repurchase price of 90.6% of face value, and reduced the outstanding principal on these notes to about $364.7 million. Emergent states that the bond buyback aligns with its goal of strengthening its financial profile and managing its balance sheet during a multi‑year transformation. The company reports a strong cash position and access to an additional $50 million under its asset‑based revolving credit facility, and plans to monitor market conditions to evaluate timing for potential refinancing of the remaining notes. Management will discuss this milestone and its broader transformation progress at upcoming Wells Fargo and H.C. Wainwright healthcare investor conferences in September 2026.
Emergent BioSolutions (NYSE:EBS) announced a contract modification valued at approximately $24 million from BARDA, part of ASPR within HHS, to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for U.S. anthrax preparedness efforts. CYFENDUS® received FDA approval in July 2023 as a two-dose post‑exposure prophylaxis anthrax vaccine for adults 18–65 when used with recommended antibacterial drugs. The company highlighted a recent NEJM Evidence study examining CYFENDUS® use after anthrax exposures in Wyoming. Emergent said this award builds on its long-standing U.S. government partnership, noting an earlier 2026 delivery order valued at up to $21.5 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War.
Emergent BioSolutions (NYSE:EBS) has been awarded a new standing offer by the Government of Canada, following a competitive procurement process, to supply NARCAN® Nasal Spray nationwide. The standing offer runs from October 1, 2026 through September 30, 2029, with an option to extend for two additional years.
The arrangement allows authorized federal departments, agencies, Crown corporations, provinces, territories and other designated public sector organizations to procure NARCAN® via individual call-ups, supporting timely access to opioid overdose reversal medication. This award follows an existing 5-year standing offer expiring in September 2026. NARCAN® Nasal Spray is described as the only 4 mg intranasal naloxone spray in Canada with a four-year shelf life.
Emergent BioSolutions (NYSE: EBS) marked International Overdose Awareness Day by reinforcing its focus on opioid overdose education and preparedness. The company is continuing its Ready to Rescue campus campaign with Release Recovery founder Zac Clark to promote carrying and using NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg in U.S. colleges.
Emergent is also extending its awareness efforts in Canada through a partnership with professional baseball player Davis Schneider, whose advocacy highlights the impact of opioid poisonings and the importance of naloxone access. The company underscores that NARCAN® Nasal Spray is an over-the-counter product in the U.S. that can reverse opioid overdoses when used promptly and followed by emergency care.
Emergent BioSolutions (NYSE:EBS) reported Q2 2026 total revenues of $234.3 million, up 66% year over year, driven mainly by higher U.S. government sales of smallpox and other medical countermeasure (MCM) products. Adjusted net income was $30.9 million (up 134%) and adjusted EBITDA reached $96.5 million with a 41% margin. GAAP results showed a net loss of $180.2 million, largely due to a $191.3 million non-cash impairment on the NARCAN asset group, even as gross margin expanded to 50% and adjusted gross margin to 58%.
The company is implementing a restructuring, including about 90 role reductions and creating a new Growth organization, targeting approximately $40 million in annualized savings. Emergent also refinanced its term loan with a new $150 million facility, executed ACAM2000 and BAT contract modifications totaling over $117 million, secured new manufacturing partnerships, and obtained additional international approvals for ACAM2000.
Emergent BioSolutions (NYSE:EBS) underscores the growing need for biological threat preparedness as governments confront risks linked to geopolitical conflict, AI, synthetic biology and potential misuse of biological agents. The company highlights calls from European health officials and AI industry leaders for stronger safeguards, including screening of synthetic DNA and RNA orders.
Emergent points to recent anthrax-related events in Ukraine and Wyoming and notes a new NEJM Evidence study on the use of its CYFENDUS® anthrax vaccine for post-exposure prophylaxis in Wyoming. The release reiterates CYFENDUS®’s indication for adults 18–65 when used with antibacterial drugs and details key safety information, including contraindications, pregnancy risk, and common injection-site and systemic adverse reactions. Emergent positions itself as a long-standing partner to governments in delivering medical countermeasures against threats such as anthrax, smallpox, mpox and botulism.
Emergent BioSolutions (NYSE: EBS) announced it will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. Eastern time to discuss its second quarter 2026 financial results. Investors can access the call live via webcast on the company’s Investors page or by registering in advance for telephone participation to receive dial-in details, a unique passcode, and registrant ID. A replay of the call will also be available on the Investors page.
Emergent BioSolutions (NYSE:EBS) received a $52.7 million contract modification from ASPR/HHS to supply ACAM2000® smallpox and mpox vaccine, ancillaries, and diluent replacement lots for U.S. preparedness. Deliveries are expected to begin in June 2026 under an existing 10-year contract.
The announcement follows recent approvals of ACAM2000® for high-risk adults in Saudi Arabia and an expanded mpox indication in Singapore. The release also reiterates ACAM2000®’s indication and detailed safety information, including boxed warnings and common adverse reactions.
Emergent BioSolutions (NYSE:EBS) received a contract modification worth approximately $64.5 million from ASPR, part of U.S. HHS, under its existing 10-year agreement to supply BAT botulism antitoxin.
BAT treats symptomatic botulism in adults and pediatric patients; effectiveness is based on animal studies. Key warnings include hypersensitivity, infusion reactions, serum sickness, blood sugar test interference, and rare serious adverse reactions.
Emergent BioSolutions (NYSE:EBS) announced that senior management will participate in several upcoming investor conferences in late May and early June 2026.
Events include Goldman Sachs leveraged finance and global healthcare conferences, the Benchmark Healthcare House Call Virtual Investor Conference, and the Jefferies Global Healthcare Conference with webcast presentations and options for one-on-one meetings.